Magdalena Angelova
Overview
Explore the profile of Magdalena Angelova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Broekema N, Mertens M, Angelova M, Orzalli M, Oh H, Knipe D
Virology
. 2023 Jun;
585:34-41.
PMID: 37271042
DNA virus infection triggers an antiviral type I interferon (IFN) response in cells that suppresses infection of surrounding cells. Consequently, viruses have evolved mechanisms to inhibit the IFN response for...
2.
Neuhausser W, Oh H, Eggan P, Angelova M, Kirchner R, Eggan K, et al.
Bio Protoc
. 2021 Mar;
10(17):e3748.
PMID: 33659408
The efficiency of cleavage of individual CRISPR/Cas9-sgRNAs remains difficult to predict based on the CRISPR target sequence alone. Different intracellular environments (dependent on cell type or cell cycle state for...
3.
Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9
Oh H, Neuhausser W, Eggan P, Angelova M, Kirchner R, Eggan K, et al.
Elife
. 2019 Dec;
8.
PMID: 31789594
Herpes simplex virus (HSV) establishes lifelong latent infection and can cause serious human disease, but current antiviral therapies target lytic but not latent infection. We screened for sgRNAs that cleave...
4.
Hoyos-Bachiloglu R, Chou J, Sodroski C, Beano A, Bainter W, Angelova M, et al.
J Clin Invest
. 2017 Nov;
127(12):4415-4420.
PMID: 29106381
Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated Mycobacterium abscessus, Streptococcus viridians bacteremia, and cytomegalovirus...
5.
Angelova M, Machado H, Swan K, Morris C, Sullivan D
Bio Protoc
. 2016 Aug;
3(15).
PMID: 27547783
Extravillous trophoblast (EVT) migration and invasion through the decidualized endometrium is essential to successful placentation. SGHPL-4 cells, an EVT cell line derived from first trimester placenta, is a widely used...
6.
Saba N, Angelova M, Lobelle-Rich P, Levy L
Leuk Res
. 2015 Aug;
PMID: 26298175
Targeting components of the B-cell receptor (BCR) pathway have dramatically improved clinical outcomes in a variety of B-cell malignancies. Despite the well-documented pathogenic role of BCR precursor (pre-BCR) pathway in...
7.
Angelova M, Ortiz-Meoz R, Walker S, Knipe D
J Virol
. 2015 Jun;
89(16):8474-83.
PMID: 26041297
Unlabelled: O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) is an essential cellular enzyme that posttranslationally modifies nuclear and cytoplasmic proteins via O-linked addition of a single N-acetylglucosamine (GlcNAc) moiety. Among the many...
8.
Angelova M, Ferris M, Swan K, McFerrin H, Pridjian G, Morris C, et al.
Virol J
. 2014 Dec;
11:218.
PMID: 25514828
Background: KSHV is a tumorigenic γ-herpesvirus that has been identified as the etiologic agent of Kaposi's sarcoma (KS), a multifocal highly vascularized neoplasm that is the most common malignancy associated...
9.
Yan Z, Bryant K, Gregory S, Angelova M, Dreyfus D, Zhao X, et al.
mBio
. 2014 Jul;
5(4):e01318-14.
PMID: 24987091
The catalytic site of the HIV integrase is contained within an RNase H-like fold, and numerous drugs have been developed that bind to this site and inhibit its activity. Herpes...
10.
Abboud E, Shelby B, Angelova M, Nelson A, Ferris M, McFerrin H, et al.
Ochsner J
. 2013 Mar;
13(1):66-75.
PMID: 23532945
Background: Kaposi sarcoma-associated herpesvirus (KSHV) encoded G protein-coupled receptor (vGPCR) is a constitutively active lytic phase protein with significant homology to the human interleukin-8 receptor. vGPCR is necessary and sufficient...